AAPS eChalk Talk Webinar: DMPK Strategies for Advancing Preclinical Development of AOC Therapeutics

Webinar Overview:

Antibody-oligonucleotide conjugates (AOCs) are an emerging therapeutic modality that combines the targeting capability of antibodies with the gene-regulation potential of oligonucleotides. While this hybrid design creates exciting opportunities for targeted therapy, it also introduces unique pharmacokinetic and biotransformation challenges that differ from traditional biologics or oligonucleotide drugs.

The presentation outlines a holistic DMPK strategy for AOC development. Specifically, it details the critical ADME investigations required for the intact conjugate, linker, and oligonucleotide payload. A significant focus is placed on addressing key challenges in AOC DMPK studies, including the selection of appropriate analytical platforms for preclinical PK assessments and the characterization of biotransformation. These points are illustrated and reinforced through relevant case studies.